Evidence map›Paper›PMID 37895478›Full record

ReviewLife (Basel, Switzerland)2023

Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management.

Nina Łabędź, Cristian Navarrete-Dechent, Honorata Kubisiak-Rzepczyk, Monika Bowszyc-Dmochowska, Anna Pogorzelska-Antkowiak, Paweł Pietkiewicz

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07331792 (Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07331792 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor

TypeinterventionalSponsorCombined Military Hospital AbbottabadRan2026 to 2026Enrolled86ConditionsPityriasis VersicolorArmsTopical 1 % clotrimazole twice daily 2 weeks, Oral itraconazole 200mg daily for 5 days
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nina ŁabędźDepartment of Dermatology, Paediatric Dermatology and Oncology, Biegański's Hospital, 91-347 Łódź, Poland.
Cristian Navarrete-DechentDepartment of Dermatology, Melanoma and Skin Cancer Unit, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.ORCID 0000-0003-4040-3640
Honorata Kubisiak-RzepczykDepartment of Dermatology and Venerology, Poznan University of Medical Sciences, 60-356 Poznań, Poland.
Monika Bowszyc-DmochowskaCutaneous Histopathology and Immunopathology Section, Department of Dermatology, Poznan University of Medical Sciences, 60-356 Poznań, Poland.ORCID 0000-0001-8221-7622
Anna Pogorzelska-AntkowiakEsteDerm Private Dermatology Clinic, 43-100 Tychy, Poland.ORCID 0000-0001-8550-5427
Paweł PietkiewiczDermatology Private Practice, 60-814 Poznań, Poland.ORCID 0000-0001-7262-2456
Poznan University of Medical Sciences · PLPontificia Universidad Católica de Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This narrative review presents a comprehensive overview of the diagnosis and management of pityriasis versicolor (PV), a common superficial fungal infection caused by the yeast Malassezia. PV is characterised by scaly hypopigmented or hyperpigmented patches, primarily affecting the upper trunk, neck, and upper arms. Regarding commensal interactions, Malassezia utilises nutrient sources without affecting the human host. In cases of pathogenicity, Malassezia can directly harm the host via virulence factors or toxins, or indirectly by triggering damaging host responses. The diagnosis typically relies on recognising characteristic clinical features. Due to the wide variability in its clinical presentation, recognising the differential diagnosis is critical. In this paper, we discuss the clinical differentials, with their dermatoscopic presentation, but also describe a range of helpful diagnostic techniques (microscopy, conventional and ultraviolet-induced fluorescence dermatoscopy, and confocal microscopy). Topical therapies are the primary treatment for PV, encompassing non-specific antifungal agents like sulphur with salicylic acid, selenium sulphide 2.5%, and zinc pyrithione. Additionally, specific topical antifungal medications with either fungicidal or fungistatic properties may also be incorporated into the topical treatment regimen, such as imidazoles, allylamines, and ciclopirox olamine. Systemic therapies might occasionally be used. Patient education and the promotion of good personal hygiene are pivotal to reduce the risk of recurrence. In recurrent cases, particularly during warmer and more humid periods, prolonged prophylaxis with topical agents should be considered.

Indexed as

confocal microscopydermatoscopyfungal infectionsimagingMalasseziamicroscopyPitryrosporumtinea versicolortreatmentultraviolet radiationyeast

Identifiers

PMID37895478
PMCPMC10608716
OpenAlexW4387859824

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.